← Back to Search

Continuing vs Holding Metformin for Type 2 Diabetes

Phase 4
Waitlist Available
Research Sponsored by University of Illinois at Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during hospitalization
Awards & highlights
No Placebo-Only Group
Drug Has Already Been Approved
Pivotal Trial

Summary

This trial compares the effects of continuing metformin medication versus stopping it during hospitalizations for internal medicine services. It looks at how this affects glucose control, acidosis, abdominal symptoms, length of hospital

Who is the study for?
This trial is for adults over 18 with Type 2 Diabetes who are already taking Metformin and have been admitted to an internal medicine service. It's not for those with severe acidosis, pregnant women, patients on dialysis, individuals unable to take oral meds or consent, or those with specific heart or liver conditions.
What is being tested?
The study tests whether continuing the diabetes medication Metformin during hospital stays is better than stopping it. The focus is on how this affects blood sugar control, risk of acidosis and abdominal issues, length of hospital stay, and survival rates.
What are the potential side effects?
While the trial itself doesn't introduce new treatments that could cause side effects beyond what participants may already experience from Metformin use (like digestive upset), monitoring will include potential complications from continued use in a hospitalized setting.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during hospitalization
This trial's timeline: 3 weeks for screening, Varies for treatment, and during hospitalization for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean glucose levels
Other study objectives
Mean glucose levels while receiving metformin in the continuation arm and while not receiving metformin in the discontinuation arm

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Active Control
Group I: Metformin discontinuationActive Control1 Intervention
Holding home metformin regimen during hospitalization to an internal medicine service
Group II: Metformin continuationActive Control1 Intervention
Continuation of home metformin regimen during hospitalization to an internal medicine service

Find a Location

Who is running the clinical trial?

Emily HannersUNKNOWN
Peggy ChoyeUNKNOWN
Dulal BhaumikUNKNOWN
Julie JunUNKNOWN
Avisek DattaUNKNOWN
Annesti ElmasriUNKNOWN
University of Illinois at ChicagoLead Sponsor
640 Previous Clinical Trials
1,568,408 Total Patients Enrolled
3 Trials studying Diabetes
3,822 Patients Enrolled for Diabetes
Hailey SoniUNKNOWN
Colin GoodmanUNKNOWN
~196 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top